PF-04449613

Stock Code: 3573799
Manufacturer Part No: PZ0349-5MG
Order Now for 7 day delivery
£131.76 (exc VAT) per 5MG
Quantity: - +

Biochem/physiol Actions


PF-04449613 is a potent and selective cGMP-competitive PDE9A inhibitor (IC50 = 24 nM; IC50 >800 nM against other PDE members), displaying more than 1000-fold selectivity over the majority of 79 non-PDE targets investigated with the exception of cytochrome P450 2C19 (IC50 = 1600 nM), dopamine transporter (Ki = 110 nM), µ-opioid receptor (Ki = 3500 nM), and sodium channel binding site 2 (Ki = 470 nM). PF-4449613 is shown to effectively increase cGMP levels in brain (1-10 mg/kg s.c.; mice) and CSF (1-32 mg/kg s.c.; rats and cynomolgus macaques) in vivo with good brain penetration (brain/plasma ratio of 0.8 in mice). PF-04449613 is effective against D-amphetamine-induced auditory gating deficit (by 43% with 1 mg/kg PF-04449613 s.c.; 1 mg/kg AMP i.v.) and transverse aortic constriction-caused cardiac dysfunction (30 mg/kg/12 h p.o.) in mice in a NOS-independent manner.


Legal Information


Pfizer is a registered trademark of Pfizer, Inc.


Sold for research purposes under agreement from Pfizer Inc.


Packaging


5, 25 mg in glass bottle

Colourwhite to beige
Quality Level100
ManufacturerSIGMA-ALDRICH
SolubilityDMSO: 10 mg/mL, clear
Formpowder
Assay≥98% (HPLC)

There are no downloads for this product.